Pharmaceutical and Life Sciences Sector Task Force: Membership and engagement
On this page
Task force membership
| Name | Title | Organization |
|---|---|---|
| Martin LeBlanc (Co-Chair) | Co-founder and Vice-chairman | CellCarta Biosciences Inc. |
| Michelle Boudreau (Co-Chair) | Former Associate Assistant Deputy Minister at Health Canada | N/A |
| Alan Walshe | General Manager | Takeda |
| An Van Gerven | President | Pfizer Canada |
| Arima Ventin | Head, Market Access and Government Affairs | AbbVie Canada |
| Bettina Hamelin | President and CEO | Innovative Medicines Canada (IMC) |
| Brigitte Nolet | Head of Global Access for the Pharmaceutical Division, formely Roche Canada President and CEO | Roche |
| David D. Jones | President and Managing Director | Merck Canada |
| Dimitri Gitas | Country President (Canada) | Novartis |
| Frédéric Ors | Co‑Founder, President, and CEO | Aramis Biotechnologies |
| Gaby Bourbara | President | AstraZeneca Canada |
| Gill Stafford | Country Head Commercial Operations | CSL Seqirus Canada |
| Helen Trifonopoulos | Vice President, Market Access, Public Affairs and Patient Programs | Bristol Myers Squibb Canada |
| Iain Graham | President and General Manager | Novo Nordisk Canada |
| James Guy | General Manager | Sanofi Canada |
| Laetitia Decroix Guilloux | President, Canada | Johnson & Johnson |
| Mathilde Merlet | President and General Manager | Eli Lily |
| Michèle De Guise (observer) | President and CEO | Institut national d'excellence en santé et services sociaux (INESSS) |
| Patricia Gauthier | Regional Head CA/UK/AUS | Moderna |
| Paul Petrelli | Vice President and General Manager | Gilead |
| Sridhar Venkatesh | President & General Manager | GSK Canada |
| Stéphanie Michaud | President and CEO | BioCanRx |
| Suzanne McGurn | President and CEO | Canada’s Drug Agency (CDA-AMC) |
| Tamer Mohamed | Founder & CEO | Aspect Biosystems |
| Ugur Gunaydin | Vice-President and General Manager | Amgen Canada Inc. |
| Wendy Zatylny | President and CEO | BIOTECanada |
| Rithesh Mishra | Interim CEO & VP Finance and Admin | Boehringer Ingelheim Canada |
Co-chair additional engagements
In addition to formal task force deliberations, the co-chairs undertook targeted bilateral engagements with a range of organizations across the pharmaceutical and life sciences ecosystem, spanning health system delivery, regulation, patients and the pharmaceutical value chain. These discussions provided insights into system-wide dynamics and cross-cutting challenges across access, pricing and supply chains, informing the co-chairs’ understanding and strengthening their leadership of the task force.
- Applied Pharmaceutical Innovation
- Best Medicines Coalition
- Canada’s Drug Agency
- Canadian Association for Pharmacy Distribution Management (CAPDM)
- Canadian Critical Drug Initiative
- Canadian Life & Health Insurance Association (CLHIA)
- Canadian Organization for Rare Disorders (CORD)
- Canadian Pharmacists Association (CPhA)
- HealthCareCAN
- McKesson Canada
- pan-Canadian Pharmaceutical Alliance (pCPA)
- Patented Medicine Prices Review Board (PMPRB)
- Sick Kids, Child Health Policy Accelerator
- Vital - Canada’s Pharmaceutical Supply Chain Alliance
Generics and biosimilar sector engagement:
- APOTEX Canada
- Biosimilars Canada
- Canadian Generic Pharmaceutical Association (CGPA)
- Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA)
- Groupement provincial de l'industrie du médicament (GPIM)
- Juno Pharma Canada Inc.
- Laboratoire Riva
- Pharmascience Inc.
- Sandoz Canada Inc.
- Sterinova
- Sun Pharma Canada Inc.